Bank Of New York Mellon Corp Nuvation Bio Inc. Transaction History

Bank Of New York Mellon Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$1.68 - $2.5 $788,524 - $1.17 Million	469,360 New	469,360 $901,000
Q3 2022 Nov 14, 2022	BUY	$0.29 - $4.04 $11,615 - $161,822	40,055 Added 10.0%	440,523 $987,000
Q2 2022 Aug 15, 2022	SELL	$3.24 - $5.85 $294,525 - $531,782	-90,903 Reduced 18.5%	400,468 $1.3 Million
Q1 2022 May 11, 2022	BUY	$4.6 - $8.83 $2,313 - $4,441	503 Added 0.1%	491,371 $2.58 Million
Q4 2021 Feb 11, 2022	BUY	$7.75 - $10.05 $1.61 Million - $2.09 Million	207,498 Added 73.23%	490,868 $4.17 Million
Q3 2021 Nov 12, 2021	BUY	$7.78 - $10.0 $1.05 Million - $1.35 Million	134,797 Added 90.73%	283,370 $2.82 Million
Q2 2021 Aug 11, 2021	BUY	$9.22 - $14.48 $1.15 Million - $1.8 Million	124,453 Added 515.97%	148,573 $1.38 Million
Q1 2021 May 13, 2021	BUY	$9.0 - $14.57 $217,080 - $351,428	24,120 New	24,120 $252,000

158

157M

3.2K

98.7K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $613M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.